Document is current
Any future updates will be listed below
-
Authors
van Genugten, Jasper H.L.T. https://orcid.org/0000-0003-1157-3763
Fennell, Dean A. https://orcid.org/0000-0001-7373-1312
Baas, Paul
- License Information
-
More Information
Article History
Received: 12 September 2025
Revised: 25 November 2025
Accepted: 15 December 2025
First Online: 7 January 2026
Competing interests
: JHLTvG declares no competing interests. DAF reports grants from Aldeyra, Astex Therapeutics, Bayer, BMS and Boehringer Ingelheim, Owkin; non-financial support from BerGenBio, Clovis, Eli Lilly, MSD, Roche, and Tesaro GSK; personal fees from Aldeyra, Cambridge Clinical Laboratories, Ikena, Opna Bio, Owkin, RS Oncology, Roche, MSD. PB reports institutional payments and grants: study grants from BMS, Pfizer, and Roche; consultant and advisory services for MSD, BMS, Aduro, BoehringerIngelheim, Targovax and Verastem.
